Cue Biopharma, Inc. is developing a unique class of biologics aimed at disease-specific T cell modulation via its Immuno-STAT platform targeting autoimmune, inflammatory, and oncology indications. Its lead candidate, CUE-401, is advancing toward IND filing in Q2 2026, supported by strategic partnerships including Boehringer Ingelheim. Despite these advances, the company continues to report substantial operating losses and negative cash flows, constraining financial sustainability. Regulatory compliance challenges, competitive pressures, and Nasdaq listing risks add material uncertainty to its growth trajectory.